Heart Transplant — Cost, Top Hospitals & Success Rates | MyMedicPlus

A heart transplant — formally called orthotopic cardiac transplantation — is the surgical replacement of a failing native heart with a healthy donor heart from a brain-dead or cardiac-death donor. It remains the definitive treatment for end-stage heart failure (HF) when all medical and device therapies have been exhausted. The procedure was first performed by Dr. Christiaan Barnard in Cape Town on 3 December 1967; today, approximately 6,000 transplants are carried out worldwide each year, with the International Society for Heart and Lung Transplantation (ISHLT) registry documenting outcomes for over 130,000 recipients.

The standard surgical approach is orthotopic transplantation, in which the recipient's native heart is excised and the donor heart is implanted in its anatomical position. Two principal anastomotic techniques are used: the bicaval technique, which anastomoses the donor superior vena cava (SVC) and inferior vena cava (IVC) separately to the recipient cavae, and the older biatrial (Lower-Shumway) technique, which joins donor and recipient right atrial cuffs. Bicaval anastomosis is now preferred at most high-volume centres because it better preserves sinoatrial node function, reduces tricuspid regurgitation, and lowers the incidence of sinus node dysfunction and atrial flutter compared with the biatrial method.

Donor heart viability is critically time-dependent. Cold ischaemia time — the interval between donor aortic cross-clamping and restoration of recipient coronary perfusion — should ideally remain under 4 hours and must generally not exceed 6 hours. Prolonged cold ischaemia dramatically increases primary graft dysfunction (PGD) risk and is an independent predictor of 30-day mortality. Hearts are preserved with cardioplegic solution (e.g., University of Wisconsin or Celsior solution) at 4°C during transport. Normothermic machine perfusion systems (e.g., the Transmedics Organ Care System) are increasingly used to extend viability and assess marginal donor hearts prior to implantation.

Heart transplantation is reserved for patients with end-stage cardiac disease — defined as persistent NYHA functional Class III–IV symptoms despite optimal guideline-directed medical therapy (GDMT), cardiac resynchronisation therapy (where indicated), and, in eligible patients, implantable cardioverter-defibrillator (ICD) or mechanical circulatory support. The leading underlying diagnoses among adult recipients are:

• Ischaemic cardiomyopathy (~35% of recipients): Left ventricular dysfunction secondary to prior myocardial infarction or multivessel coronary artery disease not suitable for revascularisation.
• Dilated (non-ischaemic) cardiomyopathy (~40%): Idiopathic, familial (e.g., lamin A/C or titin gene mutations), peripartum, alcohol-related, or chemotherapy-induced cardiomyopathy.
• Valvular cardiomyopathy (~4%): End-stage LV dysfunction from longstanding mitral or aortic valve disease.
• Congenital heart disease (~3% adults; higher in paediatric recipients): Complex anatomy with exhausted surgical options, including failed Fontan circulations.
• Refractory arrhythmias: Ventricular tachycardia storms unresponsive to ablation or device therapy.
• Hypertrophic cardiomyopathy: Burned-out obstructive or non-obstructive HCM with severe systolic dysfunction.
• Restrictive cardiomyopathy: Including cardiac amyloidosis (AL type responds poorly; wild-type or variant transthyretin amyloidosis may be suitable).

In children under 18, congenital heart disease and cardiomyopathy together account for over 90% of transplant indications. Combined heart-liver or heart-kidney transplants are performed in selected patients with coexisting organ failure.

Recipient selection balances the potential survival benefit of transplantation against operative risk and the ethical obligation to allocate scarce donor organs equitably. Evaluation is performed by a multidisciplinary heart failure team including cardiologists, surgeons, nurse coordinators, social workers, and psychiatrists.

General candidacy criteria include: end-stage HF with expected 1-year mortality >50% without transplant; LVEF typically ≤25% with peak VO₂ ≤14 mL/kg/min (or ≤50% predicted) on cardiopulmonary exercise testing; or VO₂ ≤12 mL/kg/min in patients on beta-blockers.

Absolute contraindications include: irreversible pulmonary hypertension with pulmonary vascular resistance (PVR) >6 Wood units unresponsive to vasodilator challenge (PVR >5 WU after nitric oxide inhalation or prostacyclin challenge); active systemic infection; active or recently treated solid organ malignancy within 5 years (except non-melanoma skin cancers); irreversible significant end-organ dysfunction (eGFR <30 mL/min unless combined heart-kidney is planned; severe hepatic cirrhosis); severe peripheral or cerebrovascular disease limiting rehabilitation; severe obesity (BMI >35 kg/m²) prior to weight-loss intervention; and active substance abuse or non-adherence that cannot be adequately addressed.

Relative contraindications — weighed centre-by-centre — include: age above 70 years (increasing numbers of selected recipients are >70); diabetes mellitus with significant end-organ damage; severe frailty; and active psychiatric illness. Fixed high PVR (transpulmonary gradient >15 mmHg) raises the risk of acute right heart failure of the donor heart; some centres use a left ventricular assist device (LVAD) as a bridge to transplantation while the pulmonary pressures fall.

Orthotopic transplantation is performed via median sternotomy under cardiopulmonary bypass (CPB). The native heart is excised, typically preserving posterior left and right atrial cuffs. In the bicaval technique — now the preferred approach — the recipient SVC and IVC are anastomosed end-to-end to the corresponding donor venae cavae, followed by left atrial, pulmonary artery, and aortic anastomoses. In the biatrial technique, a large recipient right atrial cuff is sutured to the donor right atrium as a single anastomosis; this is faster but distorts atrial geometry and is associated with higher rates of sinus node dysfunction, requiring permanent pacemaker implantation in up to 15% of cases compared with ~5% with bicaval anastomosis.

The donor heart is reperfused after aortic clamp release, and defibrillation restores rhythm. Intraoperative transesophageal echocardiography (TEE) guides assessment of ventricular function, anastomotic integrity, and de-airing. Right ventricular (RV) dysfunction — caused by pre-existing elevated recipient PVR and donor RV adaptation — is the most common immediate post-operative complication and is managed with inhaled nitric oxide, milrinone, and vasopressin. Primary graft dysfunction (PGD), defined by ISHLT consensus criteria, ranges from mild (requiring low-dose inotropes) to severe (requiring mechanical circulatory support including ECMO or short-term VAD).

Bridge-to-transplant strategies for patients deteriorating on the waiting list include: intra-aortic balloon pump (IABP), percutaneous microaxial flow devices (Impella), continuous-flow left ventricular assist devices (CF-LVAD, e.g., HeartMate 3 or HeartWare HVAD), and biventricular assist devices (BiVAD) or total artificial hearts (SynCardia) for biventricular failure. CF-LVADs bridging to transplant have been associated with comparable post-transplant survival to non-bridged recipients in experienced centres.

For appropriately selected patients, heart transplantation offers substantial survival benefit and quality-of-life improvement over medical therapy alone.

Survival statistics from the ISHLT 2023 registry (adult recipients, 1992–2022) show: median survival of approximately 13.5 years for all recipients; 85% 1-year survival; 70% 5-year survival; and ~50% 10-year survival. Recipients who survive the first year have a conditional median survival of over 14 years. Younger recipients (age 18–29 at transplant) have median survivals exceeding 15 years. Paediatric recipients have median survivals of over 22 years when transplanted under age 1.

Functional outcomes are remarkable: over 90% of surviving recipients report no activity limitations at 1 year post-transplant, a dramatic contrast to their pre-transplant NYHA Class III–IV status. Maximal oxygen uptake (peak VO₂) increases from a mean of ~12 mL/kg/min pre-transplant to ~20 mL/kg/min at 1 year, reflecting return of near-normal cardiac output. Employment rates among working-age recipients return to 30–40% within 2 years. Exercise capacity, psychological well-being, and freedom from hospitalisation all improve significantly compared with advanced HF managed medically or with LVAD alone.

Heart transplant is the only intervention proven to extend survival in patients with end-stage HF who are ineligible for or have failed LVAD destination therapy. When performed at high-volume centres (>12 transplants/year), early mortality rates fall to 5–7%, comparable to other major cardiac surgeries.

Heart transplant carries significant short- and long-term risks that require lifelong medical management.

Immediate and early (within 30 days) complications:

• Primary graft dysfunction (PGD): The leading cause of 30-day mortality (~40% of early deaths). Severe PGD requires mechanical circulatory support; mortality with severe PGD approaches 60–70% despite support.
• Acute right ventricular failure: From unmasked recipient pulmonary hypertension; treated with inhaled NO, PDE-5 inhibitors, and temporary RV support.
• Bleeding and re-exploration: 10–15% of recipients require surgical re-exploration for haemostasis.
• Stroke: Perioperative stroke in ~2–4% of recipients, related to CPB, air embolism, or hypoperfusion.
• Acute cellular rejection (ACR): Typically occurs in the first 6 months; ISHLT grading 0, 1R (mild), 2R (moderate), 3R (severe). Treated with high-dose corticosteroids; severe/recurrent rejection with anti-thymocyte globulin.
• Primary infections: Bacterial pneumonia, wound infections, and urinary tract infections in the first 30 days are common due to surgical intervention and high-dose early immunosuppression.

Medium-term risks (months 1–12): Opportunistic infections peak: cytomegalovirus (CMV) disease (most common; prophylaxis with valganciclovir), Pneumocystis jirovecii pneumonia (PCP; prophylaxis with trimethoprim-sulfamethoxazole), aspergillosis. Antibody-mediated rejection (AMR) — harder to treat and associated with worse outcomes than ACR — is detected by biopsy (pAMR grading) and C3d/C4d staining. Renal dysfunction from calcineurin inhibitor nephrotoxicity begins early and may progress to chronic kidney disease requiring dialysis in 5–10% of recipients by 10 years.

Lifelong, structured surveillance is essential after heart transplantation to detect rejection, graft vasculopathy, and immunosuppression toxicity.

Endomyocardial biopsy (EMB) remains the gold standard for rejection surveillance. The standard schedule at most centres is: weekly for the first month, then every 2 weeks for months 2–3, monthly for months 4–6, every 3 months for year 1, and semi-annually or annually thereafter. EMB is performed via right internal jugular or femoral vein access, obtaining 4–6 samples from the right ventricular septum for histopathological analysis (ISHLT cellular rejection grading) and immunohistochemistry (AMR). Non-invasive alternatives including gene expression profiling (AlloMap) and donor-derived cell-free DNA (dd-cfDNA, e.g., Allosure) are validated for low-risk surveillance in stable recipients, reducing the need for biopsy after 6–12 months.

Echocardiography: Transthoracic echocardiography (TTE) is performed at 1 month, 3 months, 6 months, 1 year, and annually, assessing systolic function, diastolic parameters, tricuspid regurgitation, and wall motion. New wall motion abnormalities raise suspicion for cardiac allograft vasculopathy (CAV). Cardiac MRI offers superior tissue characterisation but availability is limited.

Coronary surveillance for CAV: Annual coronary angiography starting at 1 year post-transplant is recommended to detect cardiac allograft vasculopathy, which is the leading cause of death beyond 3 years. Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) detects early diffuse intimal thickening before angiographic changes. CAV is graded by ISHLT criteria: CAV 0 (no detectable disease), CAV 1 (mild), CAV 2 (moderate), CAV 3 (severe). Once severe CAV is established, retransplantation is the only definitive option for eligible patients.

Heart transplantation is among the most expensive medical interventions, with costs distributed across evaluation, the transplant hospitalisation, and lifelong outpatient management.

Hospitalisation costs for the transplant procedure itself vary widely: in the United States, the average billed charge for the transplant episode (including 30-day readmissions) exceeds USD 1.3 million; actual paid amounts are typically USD 400,000–700,000. In the United Kingdom, NHS costs run approximately £80,000–£120,000. In India, the all-inclusive cost ranges from USD 25,000–60,000 at accredited centres such as AIIMS Delhi, Medanta — The Medicity, and Fortis Malar. In Thailand and Singapore, costs range from USD 60,000–150,000.

Immunosuppression is a major ongoing cost: branded tacrolimus (Prograf) ranges from USD 5,000–12,000/year in the US; generic tacrolimus and mycophenolate mofetil have reduced maintenance costs significantly. CMV prophylaxis (valganciclovir) adds USD 3,000–6,000/year for the first 6–12 months. Blood monitoring, clinic visits, and annual invasive surveillance procedures (EMB, coronary angiography) add USD 20,000–40,000 annually in the first year, declining thereafter.

Most developed countries cover transplant costs through national health systems or mandatory insurance. Medical tourism for heart transplantation is limited by organ allocation laws — deceased donor organs in most jurisdictions are legally allocated only to domestic residents or citizens. Living donation is not applicable to heart transplantation. International patients may access transplant programmes through regulated pathways in countries where it is legally permitted.

Given the scarcity of donor organs and the rigorous candidacy requirements, several alternative strategies are used — either as bridges to transplant or as definitive destination therapy.

Left ventricular assist device (LVAD) as destination therapy: For patients ineligible for transplant (due to age, comorbidities, or psychosocial barriers), continuous-flow LVADs (HeartMate 3, HeartWare HVAD) provide survival benefit. The MOMENTUM 3 trial demonstrated superior 2-year survival with HeartMate 3 versus HeartMate II (79% vs 60%), with significantly reduced rates of pump thrombosis and stroke. LVADs restore near-normal cardiac output, allow ambulation and rehabilitation, and have a median survival of 4–6 years with modern devices. They require anticoagulation (warfarin + aspirin) and carry risks of driveline infection, haemolysis, gastrointestinal bleeding, and right heart failure.

Cardiac resynchronisation therapy (CRT): For patients in sinus rhythm with LVEF ≤35% and QRS ≥130 ms (especially LBBB morphology), CRT-D (biventricular pacemaker + ICD) improves LVEF by 5–10%, reduces hospitalisation by 37%, and reduces all-cause mortality by 36% in optimally selected patients (CARE-HF, COMPANION trials). CRT-D should be maximised before listing for transplantation.

Optimised GDMT: Quadruple therapy with ACE inhibitor/ARNi (sacubitril/valsartan), beta-blocker, MRA (spironolactone/eplerenone), and SGLT2 inhibitor (empagliflozin/dapagliflozin) has dramatically improved survival and functional outcomes in HFrEF, and some patients stabilise enough to be removed from transplant waiting lists. SGLT2 inhibitors added approximately 25% relative risk reduction in HF hospitalisation and cardiovascular death in the EMPEROR-Reduced and DAPA-HF trials.

Palliative and hospice care: For patients ineligible for transplant or LVAD who decline further intervention, coordinated palliative care focusing on symptom management (diuretics, opioids for dyspnoea, anxiolytics) significantly improves comfort and quality of remaining life.